In vivo experiments using subcutaneous prostate cancer xenografts indicated that iRGD-modified liposomes significantly enhanced the antisense oligonucleotide against androgen receptor accumulation and reduced the androgen receptor expression in prostate tumors. The gene discussed is AR; the disease is Familial prostate cancer.